ENTRADA THERAPEUTICS
Live / Registered — Registered (as of 15 Oct 2024)
What this means for you
Registered since 15 Oct 2024. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 15 Oct 2030: the §8 declaration of use).
Record
- Serial number
- 97673254
- Registration number
- 7538588
- Mark type
- Word mark
- Filed
- 11 Nov 2022
- Published for opposition
- 07 Nov 2023
- Registered
- 15 Oct 2024
- Next maintenance filing
- §8 declaration of use, due by 15 Oct 2030 (grace period to 15 Apr 2031)
- Attorney of record
- Stephanie H. Bald
Goods and services
- Class 005 — Pharmaceuticals: House mark for a line of pharmaceuticals, but not including pharmaceuticals intended to treat multiple sclerosis or related diseases or conditions related to multiple sclerosis, all of the foregoing specifically excluding pharmaceutical preparations for the treatment of cancer
- Class 042 — Scientific and technological services: Pharmaceutical research and development services
Owner
- Entrada Therapeutics, Inc., Boston, MA, US
- Entrada Therapeutics, Inc., Boston, MA, US
- Entrada Therapeutics, Inc., Boston, MA, US
Prosecution history
- 15 Oct 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 15 Oct 2024 — REGISTERED-PRINCIPAL REGISTER
- 09 Sept 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 09 Sept 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 30 Jul 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 30 Jul 2024 — NON-FINAL ACTION E-MAILED
- 30 Jul 2024 — SU - NON-FINAL ACTION - WRITTEN
- 10 Jul 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 29 May 2024 — USE AMENDMENT FILED
- 29 May 2024 — USE AMENDMENT FILED
- 29 May 2024 — USE AMENDMENT FILED
- 07 Jul 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 May 2024 — TEAS STATEMENT OF USE RECEIVED
- 29 May 2024 — SOU EXTENSION 1 GRANTED